The role of growth factors in the pathogenesis of diabetic retinopathy

被引:145
作者
Grant, MB [1 ]
Afzal, A [1 ]
Spoerri, P [1 ]
Pan, H [1 ]
Shaw, LC [1 ]
Mames, RN [1 ]
机构
[1] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA
关键词
angiogenesis; IGF; IGFBP; integrins; neovascularisation; proliferative diabetic retinopathy; SDF; TNF; VEGF;
D O I
10.1517/13543784.13.10.1275
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diabetic retinopathy (DR) is the most severe of several ocular complications of diabetes. The earliest clinical signs of DR are microaneurysms and haemorrhages. Later signs include dilated, tortuous irregular veins and retinal non-profusion, leading to retinal ischaemia that ultimately results in neovascularisation. Diabetic macular oedema, which involves the breakdown of the blood-retinal barrier, also occurs and is responsible for a major part of vision loss, particularly in Type 2 diabetes. The pathogenesis of DR is very complex. Many biochemical mechanisms have been proposed as explanations for the development and progression of DR. Chronic hyperglycaemia leads to oxidative injury, microthrombi formation, cell adhesion molecule activation, leukostasis and cytokine activation. Next, ischaemia-mediated overexpression of growth factors and cytokines occurs. These factors include vascular endothelial growth factor, insulin-like growth factor-1, angiopoetin-1 and -2, stromal-derived factor-1, fibroblast growth factor-2 and tumour necrosis factor. Because of the complex interplay between these factors, targeting a single growth factor will be unlikely to result in therapeutic inhibition of angiogenesis. These growth factors no doubt act in synergy to mediate the steps of angiogenesis, including protease production, endothelial cell proliferation, migration and tube formation. This review attempts to provide an overview of perspectives regarding the pathogenesis of this disease. The focus, however, is on describing the unique features of selected relevant factors and how each growth factor may act in a synergistic manner with other factors.
引用
收藏
页码:1275 / 1293
页数:19
相关论文
共 154 条
  • [11] VEGF localisation in diabetic retinopathy
    Boulton, M
    Foreman, D
    Williams, G
    McLeod, D
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 1998, 82 (05) : 561 - 568
  • [12] Microvascular permeability is increased in both types of diabetes and correlates differentially with serum levels of insulin-like growth factor I (IGF-I) and vascular endothelial growth factor (VEGF)
    Brausewetter, F
    Jehle, PM
    Jung, MF
    Boehm, BO
    Brueckel, J
    Hombach, V
    Osterhues, HH
    [J]. HORMONE AND METABOLIC RESEARCH, 2001, 33 (12) : 713 - 720
  • [13] BROOKS HL, 2004, ANN M ASS RES VIS OP
  • [14] ANTIINTEGRIN ALPHA-V-BETA-3 BLOCKS HUMAN BREAST-CANCER GROWTH AND ANGIOGENESIS IN HUMAN SKIN
    BROOKS, PC
    STROMBLAD, S
    KLEMKE, R
    VISSCHER, D
    SARKAR, FH
    CHERESH, DA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (04) : 1815 - 1822
  • [15] INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS
    BROOKS, PC
    MONTGOMERY, AMP
    ROSENFELD, M
    REISFELD, RA
    HU, TH
    KLIER, G
    CHERESH, DA
    [J]. CELL, 1994, 79 (07) : 1157 - 1164
  • [16] Biochemistry and molecular cell biology of diabetic complications
    Brownlee, M
    [J]. NATURE, 2001, 414 (6865) : 813 - 820
  • [17] Insulin-like growth factor binding protein proteolysis
    Bunn, RC
    Fowlkes, JL
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2003, 14 (04) : 176 - 181
  • [18] Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy -: A case-control study
    Burgos, R
    Hernández, C
    Mateo, C
    Mesa, J
    Cantón, A
    Simó, R
    [J]. DIABETES CARE, 2000, 23 (01) : 80 - 83
  • [19] Insulin-like growth factor I stimulates tyrosine phosphorylation of p130Cas, focal adhesion kinase, and paxillin -: Role of phosphatidylinositol 3′-kinase and formation of a p130Cas•Crk complex
    Casamassima, A
    Rozengurt, E
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (40) : 26149 - 26156
  • [20] Chantelau E, 1997, BRIT J OPHTHALMOL, V81, P169